October 2011Poxel SA announced that €1.45mio funding has been awarded by the French Public Financing Institution OSEO for two main programs targeting type 2 diabetes.

Imeglimin has been awarded a €950K refundable grant to support the phase 2 development package currently running at Poxel. A second program, targeting direct AMPK activation, has been granted up to €500K to enable the preclinical development start. This program is co-financed by the European Union. €250K are funded by the European Fund of Regional Development (FEDER) and €250K are a refundable grant from OSEO.

Europe is committed to the Rhône-Alpes region with the European Fund of Regional Development.

These funding reflect the confidence that OSEO puts on Poxel capabilities to progress the development of these 2 innovative programs. http://www.oseo.fr/

May 2011

Poxel and co-authors publish the 1st Imeglimin paper around this phase II product pharmacology

January 20112 new persons joined Poxel team

2 new persons joined Poxel team, Ms Rodica Orza to manage clinical trials and Mr Eric Massou who brings financial expertise

December 2010Poxel SA appoints Dynamics Group Communication Agency

Poxel SA appoints Dynamics Group Communication Agency (Geneva) to support its Corporate communication
www.dynamicsgroup.ch

July 2010Poxel Raises €16 million Financing

Poxel Raises €16 million in a Series A Financing to Accelerate Pipeline Development

September 2009NATHEB Project

Poxel earns €430,000 grant from public organizations for a cooperative project named NATHEB

Project co-financed by the European Union

Europe commits with the European Fund for Regional Development